From Yahoo Finance: 2025-04-15 13:38:00

• Big American pharmaceutical corporations are increasingly seeking medications in China, with 30% of acquisitions over $50 million upfront in 2024 involving Chinese companies, up from 0% five years ago, according to CNBC.
• Chinese pharmaceutical firms are attracting attention for their development skills, quick testing on human subjects, and lower-priced medications compared to the US, prompting licensing deals with US buyers.
• The US pharmaceutical industry faces uncertainty as Chinese drugs at low prices could impact American startups, creating competition or challenges, according to experts like Tim Opler from Stifel’s global healthcare group.
• Emily Field from Barclays discusses the pharmaceutical industry’s performance, obesity medications, and US tariffs, expecting a relatively stable industry performance in the first half of the year despite uncertainties around obesity medication effectiveness and tariff impact.
• Bristol-Myers Squibb Company (NYSE:BMY) ranks 3rd in the list of best pharma stocks for long-term growth, with a strong pipeline from collaborations and acquisitions, impressive dividend growth, and a solid financial standing attracting investors.
• Despite the potential of pharmaceutical companies, AI stocks are seen as holding more promise for higher returns within a shorter timeframe, with one AI stock showing growth since the start of 2025 while popular AI stocks have declined, offering potential for significant gains at lower valuations.

Read more at Yahoo Finance: Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?